Growing Incidence Of Chronic Kidney Disease (CKD) Fueling The Market Due To Rising Prevalence Of Risk Factors And Associated Mortality Rates Is Supporting Development Across The Intravenous Iron Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Intravenous Iron Drugs Market Through 2030?

The market size for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to increase from $3.81 billion in 2025 to $4.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. Historically, this expansion has been driven by factors such as the widespread occurrence of iron deficiency anemia, the limitations of oral iron absorption, the implementation of hospital-based anemia management protocols, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.

The intravenous iron drugs market is projected for swift expansion in the coming years, reaching $6.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period stems from factors such as an escalating chronic disease burden, an expanding population of dialysis patients, a rise in cancer-related anemia occurrences, the desire for quick hemoglobin restoration, and the broadening availability of outpatient infusion services. Key trends observed in this period encompass the increasing application in managing iron deficiency anemia, its greater uptake among chronic kidney disease patients, a rising preference compared to oral iron treatments, the proliferation of single-dose iron preparations, and enhanced usage within the fields of oncology and gastroenterology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Primary Factors Are Fueling The Expansion Of The Intravenous Iron Drugs Market?

The expanding prevalence of chronic kidney disease (CKD) is anticipated to fuel the progression of the intravenous iron drugs market in the future. CKD involves a progressive decline in kidney function, preventing the kidneys from efficiently removing waste and excess fluids from the bloodstream. This rising incidence of CKD is linked to increasing cases of diabetes and hypertension, both of which contribute to kidney damage over time. Intravenous iron drugs provide assistance to CKD patients by restoring iron levels, rectifying anemia, and elevating hemoglobin, thereby enhancing oxygen delivery and minimizing the requirement for erythropoiesis-stimulating agents. For example, in July 2025, Hamadan University of Medical Sciences, an Iran-based institution, predicted that the worldwide count of new chronic kidney disease diagnoses would reach 25.06 million by 2030. Consequently, the escalating occurrence of chronic kidney disease (CKD) is propelling the expansion of the intravenous iron drugs market.

What Segment Types Are Included In The Intravenous Iron Drugs Market Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Expected To Shape The Intravenous Iron Drugs Market?

Leading companies operating in the intravenous iron drugs market are concentrating on developing novel therapies, such as intravenous (IV) iron replacement therapy, to enhance their efficacy, safety, and patient outcomes. This medical intervention involves the direct delivery of iron into the bloodstream through an intravenous infusion, primarily used to treat iron deficiency and anemia, especially in patients who cannot tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to enhance exercise capacity. Injectafer is a widely utilized intravenous iron therapy recognized for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Leading Firms Participating In The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Access The Complete Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Region Is The Dominant Market In The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Intravenous Iron Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795